Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.

Published in: Health technology assessment (Winchester, England) (2024)

; Vol. 28, No. 4. See the NIHR Funding and Awards website for further award information.

Keyphrases